Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mani Foroohar has given his Buy rating due to a combination of factors including the promising results from Intellia Therapeutics’ Phase 1 trial of lonvoguran ziclumeran for hereditary angioedema. The data presented showed a sustained attack rate reduction of 98% over the study period, with patients remaining attack-free and not requiring long-term prophylaxis for a median of 23 months. Additionally, the reduction in plasma kallikrein levels was significant and consistent across all doses, with no serious adverse events reported, indicating a strong safety profile.
Furthermore, the completion of screening for the Phase 3 HAELO trial suggests high interest from both physicians and patients, which is a positive indicator for future commercial success anticipated in 2027. Despite the current market cap of $860 million, which seems undervalued compared to the potential of the HAE opportunity, the expectation of pivotal data release and addressing of financial concerns could align the valuation more closely with its prospects.
According to TipRanks, Foroohar is an analyst with an average return of -11.0% and a 40.57% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as RegenXBio, CureVac, and Moderna.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $50.00 price target.